Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

被引：276

作者：

Caudle, K. E. ^{[1
]}

Thorn, C. F. ^{[2
]}

Klein, T. E. ^{[2
]}

Swen, J. J. ^{[3
]}

McLeod, H. L. ^{[4
]}

Diasio, R. B. ^{[5
,6
]}

Schwab, M. ^{[7
,8
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[2] Stanford Univ, Med Ctr, Dept Genet, Stanford, CA 94305 USA

[3] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Leiden, Netherlands

[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[5] Mayo Clin, Div Oncol Res, Rochester, MN USA

[6] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA

[7] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[8] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 94卷 / 06期

关键词：

SEVERE 5-FLUOROURACIL-ASSOCIATED TOXICITY; SINGLE NUCLEOTIDE POLYMORPHISMS; ADVANCED COLORECTAL-CANCER; DPYD GENE; IVS14+1G-GREATER-THAN-A MUTATION; PYRIMIDINE METABOLISM; ENZYME-ACTIVITY; HIGH PREVALENCE; DPD DEFICIENCY; INBORN-ERRORS;

D O I：

10.1038/clpt.2013.172

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org). © 2013 American Society for Clinical Pharmacology and Therapeutics.

引用

页码：640 / 645

页数：6

共 40 条

[1]

Amstutz U, 2011, PHARMACOGENOMICS, V12, P1321, DOI [10.2217/PGS.11.72, 10.2217/pgs.11.72]

[2]

Amstutz U, 2009, PHARMACOGENOMICS, V10, P931, DOI [10.2217/pgs.09.28, 10.2217/PGS.09.28]

[3]

Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population [J].

Ben Fredj, Radhia ;

Gross, Eva ;

Chouchen, Lotfi ;

B'Chir, Fatma ;

Ben Ahmed, Slim ;

Neubauer, Steffi ;

Kiechle, Marion ;

Saguem, Saad .

COMPTES RENDUS BIOLOGIES, 2007, 330 (10) :764-769

[4]

5-fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency [J].

Boisdron-Celle, M. ;

Remaud, G. ;

Traore, S. ;

Poirier, A. L. ;

Gamelin, L. ;

Morel, A. ;

Gamelin, E. .

CANCER LETTERS, 2007, 249 (02) :271-282

[5]

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer [J].

Capitain, O. ;

Boisdron-Celle, M. ;

Poirier, A-L ;

Abadie-Lacourtoisie, S. ;

Morel, A. ;

Gamelin, E. .

PHARMACOGENOMICS JOURNAL, 2008, 8 (04) :256-267

[6]

Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer [J].

Cellier, Patrice ;

Leduc, Bernard ;

Martin, Laurent ;

Vie, Brigitte ;

Chevelle, Christian ;

Vendrely, Veronique ;

Salemkour, Augustin ;

Carrie, Christian ;

Calais, Gilles ;

Burtin, Pascal ;

Campion, Loic ;

Boisdron-Celle, Michele ;

Morel, Alain ;

Berger, Virginie ;

Gamelin, Erick .

BMC CANCER, 2011, 11

[7]

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer [J].

Deenen, Maarten J. ;

Tol, Jolien ;

Burylo, Artur M. ;

Doodeman, Valerie D. ;

de Boer, Anthonius ;

Vincent, Andrew ;

Guchelaar, Henk-Jan ;

Smits, Paul H. M. ;

Beijnen, Jos H. ;

Punt, Cornelis J. A. ;

Schellens, Jan H. M. ;

Cats, Annemieke .

CLINICAL CANCER RESEARCH, 2011, 17 (10) :3455-3468

[8]

FAMILIAL DEFICIENCY OF DIHYDROPYRIMIDINE DEHYDROGENASE - BIOCHEMICAL BASIS FOR FAMILIAL PYRIMIDINEMIA AND SEVERE 5-FLUOROURACIL-INDUCED TOXICITY [J].

DIASIO, RB ;

BEAVERS, TL ;

CARPENTER, JT .

JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (01) :47-51

[9]

CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL [J].

DIASIO, RB ;

HARRIS, BE .

CLINICAL PHARMACOKINETICS, 1989, 16 (04) :215-237

[10]

POPULATION STUDY OF DIHYDROPYRIMIDINE DEHYDROGENASE IN CANCER-PATIENTS [J].

ETIENNE, MC ;

LAGRANGE, JL ;

DASSONVILLE, O ;

FLEMING, R ;

THYSS, A ;

RENEE, N ;

SCHNEIDER, M ;

DEMARD, F ;

MILANO, G .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2248-2253

← 1 2 3 4 →